Mr. Azelby is an experienced Chief Executive Officer and veteran board member who has spent over 30 years in the biopharmaceutical industry.
He served as President and Chief Executive Officer of Eliem Therapeutics, Inc., from October 2020 to February 2023. Prior to Eliem, he was the Chief Executive Officer of Alder Biopharmaceuticals, Inc., from June 2018 until it was acquired by H. Lundbeck in 2019. Before joining Alder BioPharmaceuticals, Mr. Azelby was the Chief Commercial Officer of Juno Therapeutics for three years until it was acquired by Celgene Corporation. Prior to Juno, he spent 15 years in commercial roles at Amgen, Inc.
Mr. Azelby serves on the boards of directors of Clovis Oncology, Inc., and Chinook Therapeutics, Inc. Previously, he served on the boards of directors for Eliem Therapeutics, Alder BioPharmaceuticals, Cascadian Therapeutics, Inc., and Immunomedics, Inc. He holds a BA in Economics and Religious Studies from the University of Virginia and an MBA from Harvard Business School.
What is Robert Azelby's net worth?
The estimated net worth of Robert Azelby is at least $187.80 thousand as of June 17th, 2024. Azelby owns 53,005 shares of ADC Therapeutics stock worth more than $187,797 as of December 5th. This net worth evaluation does not reflect any other investments that Azelby may own. Learn More about Robert Azelby's net worth.
How do I contact Robert Azelby?
Has Robert Azelby been buying or selling shares of ADC Therapeutics?
Robert Azelby has not been actively trading shares of ADC Therapeutics in the last ninety days. Most recently, Robert Azelby sold 6,995 shares of the business's stock in a transaction on Monday, June 17th. The shares were sold at an average price of $2.89, for a transaction totalling $20,215.55. Following the completion of the sale, the director now directly owns 53,005 shares of the company's stock, valued at $153,184.45. Learn More on Robert Azelby's trading history.
Who are ADC Therapeutics' active insiders?
Are insiders buying or selling shares of ADC Therapeutics?
In the last year, ADC Therapeutics insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $304,000.00. The most recent insider tranaction occured on December, 11th when Major Shareholder Redmile Group, Llc bought 100,000 shares worth more than $304,000.00. Insiders at ADC Therapeutics own 5.4% of the company.
Learn More about insider trades at ADC Therapeutics. Information on this page was last updated on 12/11/2024.
